Clinical trials
Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
Bethesda, MarylandAges 18–120 - NCT04453826RecruitingPhase 3
Test PD-1 plus chemo-radiation for high-risk nasopharyngeal cancer
This Phase 3 trial tests whether adding a PD-1 immunotherapy (given with chemotherapy and radiation, and also after) can improve outcomes for people with high-risk nasopharyngeal cancer. It may help by strengthening the immune system’s attack on the cancer alongside standard treatment.
Guangzhou, GuangdongAges 18–70 - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06676722RecruitingPhase 2
SBRT and two targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Xiamen, FujianAges 18–75 - NCT07376603Recruiting
Radiation therapy alone for early-stage nasopharyngeal cancer
This trial tests whether intense radiation therapy (IMRT) alone is effective for people with stage IB nasopharyngeal carcinoma (a type of head and neck cancer) that has not spread to lower lymph nodes or formed large, matted nodes. If you qualify, you would receive targeted radiation without chemotherapy.
Fuzhou, FujianAges 18–70 - NCT05397769RecruitingPhase 2
Test envafolimab with chemoradiation for advanced nasopharyngeal cancer
This trial studies whether adding envafolimab (an immune medicine) to standard chemo and radiation works better for people with locally advanced, untreated nasopharyngeal cancer. It may help the immune system attack the cancer while treatment shrinks it.
Guangzhou, GuangdongAges 18–65 - NCT05854849RecruitingPhase 3
Testing three-drug therapy versus cisplatin for recurrent NPC
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Guangzhou, GuangdongAges 18–75 - NCT07618078Recruiting
Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Beijing, Beijing MunicipalityAges 18–75 - NCT04544969Recruiting
Testing blood markers to guide chemo for metastatic nasopharyngeal cancer
This study looks at special blood markers (CTCs) to see how sensitive your cancer is to chemotherapy and to better predict how well treatment may work. If you have metastatic nasopharyngeal cancer and can’t have local treatment, this may help match you to more effective chemo plans.
Guangzhou, GuangdongAges 18–70 - NCT07459296RecruitingPhase 3
Becotatug vedotin plus sintilimab for advanced nasopharyngeal cancer
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Nanning, GuangxiAges 18–70 - NCT07392320RecruitingPhase 2
Immunotherapy or chemo pills after chemoradiation for high-risk nasopharyngeal cancer
This trial compares two options—a type of immunotherapy or a chemotherapy pill (capecitabine)—as maintenance treatment after standard chemoradiation for high-risk nasopharyngeal cancer. It aims to see which helps prevent the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT06177301RecruitingPhase 3
Comparing two drug combos for recurrent nasopharyngeal cancer
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06241612RecruitingPhase 3
Personalized neck radiation for nasopharyngeal cancer
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06857279RecruitingPhase 2
Testing HLX43 for advanced head and neck cancer
This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–75 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT06437522RecruitingPhase 2
New drug combo for recurrent head and neck cancer
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80
Hear when a new Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 69 recruiting metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.